Dual thrombolytic therapy with mutant pro-urokinase (m-pro-urokinase, HisproUK) and low dose alteplase for ischemic stroke - DUMAS

Erasmus MC, Universitair Medisch Centrum Rotterdam0 个研究点目标入组 240 人开始时间: 待定最近更新: 2024年4月15日

适应症

试验速览

暂无简介。

•- A clinical diagnosis of acute ischemic stroke;
•- A score of at least 1 on the NIH Stroke Scale;
•- CT or MRI ruling out intracranial hemorrhage;
•-Treatment is possible
•o within 4.5 hours from symptom onset or last seen well, or
•o between 4.5 to 12 hours from symptom onset or last seen well, if the infarct
•core is less than 25 mL and a penumbra is at least the same size as the infarct
•core (i.e. total ischemic volume/infarct core mismatch >= 2.0),5 or 3)
•* In case of lacunar syndrome,25 if there is a diffusion-weighted imaging and
•FLAIR mismatch4;*
•- Meet the criteria for standard treatment for IV alteplase according to
•national guidelines;
•- Contra-indication for an MRI scan (e.g., an MRI incompatible pacemaker and
•metal foreign bodies)
•- Age of 18 years or older;
•- Written informed consent (deferred).

•- Candidate for endovascular thrombectomy (i.e., no proximal intracranial large
•artery occlusion on CTA or MRA)
•- Contra-indication for treatment with IValteplase
•- Pre-stroke disability which interferes with the assessment of functional
•outcome at 30 days, i.e. mRS > 2.
•- Known pregnancy or if pregnancy cannot be excluded, i.e. adequate use of any
•contraceptive method (e.g. intrauterine devices) or sterilization of the
•subject herself
•- Participation in medical or surgical intervention trials other than DUMAS (or
•MR ASAP/ARTEMIS)

发起方